Intellia Therapeutics, Inc.

NASDAQ:NTLA

Biotechnology

Healthcare
$9.77 +0.14%

+$0.02 today

Market cap
$1.37B
Beta
1.81
P/E (TTM)
-4.6
EPS (TTM)
-$3.33
52W Low $7.95High $28.25

Volume 7.23M

Average 6.11M

NTLA Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Intellia Therapeutics, Inc.NASDAQ: NTLA

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of $34.84M rose 20.1% year over year, ahead of the +14.5% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 5.3% from the prior quarter. Over 3 fiscal years it compounded at +9.9% a year.

Context

  • Selling, general & admin amounted to 177.0% of revenue in FY2025, down 40.4 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate from 13 analysts of $96.02M (-19.8%) for the fiscal year ending Dec 2026, a slowdown from the -4.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$34.84M+5.3% QoQ
Last fiscal yearDec 2025
$119.8M-4.8% YoY
LTMMar 2026
$157.94M+14.5% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+20.1%-34.4%-54.6 pp
1 year-4.8%-19.8%-15.1 pp
3-year CAGR+9.9%+86.4%+76.5 pp
5-year CAGR+100.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
119.8M USD
Year-over-year change
-4.8%
4-year CAGR
+13.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How NTLA compares with its peers on the latest reported figures

  • NTLA's LTM Mar 2026 selling, general & admin of $157.94M is the highest of the 10 companies compared; the peer median is $68.9M.
  • Its year-over-year change of +14.5% is the 3rd highest of 10, against a peer median of -2.3%.
  • Selling, general & admin amounts to 239.0% of revenue for NTLA, versus a peer median of 120.9%.
NTLA Competitors Peer median
Selling, General & Admin for NTLA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$157.94M +14.5%+9.9%239.0%
BEAMBeam Therapeutics Inc.LTM Jun 2026$125.4M +14.0%+9.0%80.4%
PGENPrecigen, Inc.LTM Jun 2026$84.93M +155.9%+13.5%99.1%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$75.11M -30.1%+13.7%—
QUREuniQure N.V.LTM Mar 2026$71.65M +50.0%+6.1%396.0%
CRSPCRISPR Therapeutics AGLTM Sep 2026$68.9M -6.0%-10.5%273.7%
MGTXMeiraGTx Holdings plcLTM Mar 2026$52.46M -2.3%+4.4%65.8%
EDITEditas Medicine, Inc.LTM Mar 2026$46.76M -29.2%-11.0%120.9%
SANASana Biotechnology, Inc.LTM Mar 2026$44.27M -25.3%-14.8%—
CRBUCaribou Biosciences, Inc.LTM Mar 2026$36.25M -1.5%-0.1%323.5%
Peer median (excluding NTLA) $68.9M-2.3%+4.4%120.9%

Competitors are the stored peer set for NTLA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue33.05M52.12M36.28M57.88M67.67M
Cost of Revenue6.89M7.57M8.98M10.29M15.92M
Gross Profit26.16M44.55M27.3M47.59M51.75M
Gross Margin79.2%85.5%75.3%82.2%76.5%
Research & Development229.81M419.98M435.07M466.31M388.86M
Selling, General & Admin71.1M90.31M116.5M125.83M119.8M
Operating Expenses294.01M502.71M542.59M581.86M492.74M
Depreciation & Amortization6.89M7.57M8.98M10.29M15.92M
EBITDA(261M)(466.61M)(472.22M)(508.74M)(396.77M)
EBITDA Margin-789.6%-895.3%-1301.8%-879.0%-586.3%
Operating Income(267.85M)(458.16M)(515.29M)(534.26M)(440.99M)
Operating Margin-810.4%-879.0%-1420.5%-923.1%-651.7%
Interest Income1.28M8.54M49.83M47.81M29.2M
Interest Expense00000
Other Income / Expenses(42K)(16.02M)34.1M15.24M28.3M
Income Before Tax(267.89M)(474.19M)(481.19M)(519.02M)(412.69M)
Pre-Tax Margin-810.5%-909.8%-1326.5%-896.8%-609.9%
Income Tax Expense00000
Net Income(267.89M)(474.19M)(481.19M)(519.02M)(412.69M)
Net Margin-810.5%-909.8%-1326.5%-896.8%-609.9%
EPS (Basic)(3.78)(6.16)(5.42)(5.25)(3.81)
EPS (Diluted)(3.78)(6.16)(5.42)(5.25)(3.81)
Weighted Avg Shares70.89M76.97M88.77M98.85M108.38M
Weighted Avg Shares (Diluted)70.89M76.97M88.77M98.85M108.38M

Intellia Therapeutics, Inc.

NASDAQ:NTLA

Intrinsic Alpha fair value

Locked

Current Price

$9.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.